SequelSEC

CERO THERAPEUTICS HOLDINGS, INC. CERO

Biological Products, (No Diagnostic Substances) · CIK 0001870404 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$3.85M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported net income of -$1.03M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CERO THERAPEUTICS HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

CERO THERAPEUTICS HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-09-302024-06-302023-12-312023-09-30
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.85MUnavailableUnavailable-$4.36MUnavailableUnavailable-$4.40MUnavailable-$1.12M-$1.54M
Net income-$1.03MUnavailable-$4.54M-$4.86MUnavailableUnavailable-$4.23MUnavailable-$1.27M-$1.35M
Research & development$1.74MUnavailableUnavailable$2.39MUnavailableUnavailable$1.77MUnavailable$1.02M$1.28M
Weighted-average diluted sharesshares 42.18MUnavailableUnavailableshares 1.26MUnavailableUnavailableUnavailableUnavailableUnavailableshares 9.07M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$258.35K-$308.28K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$24.41K$25.75K
Diluted EPS$-0.70UnavailableUnavailable$-9.10UnavailableUnavailable$-170.22UnavailableUnavailable$-0.15
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.11MUnavailableUnavailable$1.98MUnavailableUnavailable$2.63MUnavailable$103.06K$258.01K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CERO THERAPEUTICS HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-09-302024-06-302023-12-312023-09-30
Cash & equivalents$862.76KUnavailableUnavailable$1.90MUnavailableUnavailableUnavailableUnavailable$96.87K$119.01K
Total assets$1.90MUnavailable$3.64M$3.91MUnavailableUnavailable$6.49MUnavailable$5.13M$8.47M
Current assets$1.55MUnavailable$2.73M$2.55MUnavailableUnavailable$3.71MUnavailable$1.97MUnavailable
Total liabilities$32.41MUnavailable$9.09M$8.45MUnavailableUnavailable$10.19MUnavailable$5.08M$13.95M
Current liabilities$32.41MUnavailable$9.09M$8.45MUnavailableUnavailable$9.42MUnavailable$3.51M$4.80M
Total equity incl. NCI-$30.51MUnavailable-$5.45M-$4.54MUnavailableUnavailable-$3.70MUnavailable-$42.06M-$13.77M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$8.44M$8.29M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$8.22MUnavailable$7.58M$7.08MUnavailableUnavailable$6.67MUnavailable$1.67MUnavailable

Cash flow

CERO THERAPEUTICS HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-09-302024-06-302023-12-312023-09-30
Operating cash flow-$7.89MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$186.61K-$256.12K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$13.82M$5.69M
Financing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$27.68M-$5.42M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$41.69M$13.78K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailable$0$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$27.84MUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

CERO THERAPEUTICS HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-09-302024-06-302023-12-312023-09-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.05xUnavailable0.30x0.30xUnavailableUnavailable0.39xUnavailable0.56xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CERO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-22View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

17 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.